Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

Since their introduction, drug-eluting stents (DES) have revolutionized percutaneous treatment of coronary artery disease with rates of in-stent restenosis of between 2 and 10% and significant ...

The first drug-eluting stents (DESs) were approved by the FDA in 2003, after they were shown to significantly reduce rates of restenosis and repeat revascularization, when compared with bare-metal ...

It also provides the benefits of a drug-eluting stent without the need to implant ... a GlobalData owned brand. The information on this site has been included in good faith for general ...

Elixir’s leading technology platform, the DynamX® bioadaptor, was designed to address the shortcomings of current PCI technologies such as drug-eluting stents and work toward a continued ...

10,692.69 per unit and Drug Eluting Stents (DES) including metallic DES and Bioresorbable Vascular Scaffold ... Similarly, the Authority also revised the prices of Ringer lactate injection in various ...